- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06784960
Kommunikationsstrategier för att öka avsikten med HPV-vaccination
Ett kluster randomiserat kontrollerat försök som testar kommunikationsstrategier för att öka HPV-vaccinationsavsikten: ett undersökningsexperiment
This research aims to identify communication strategies to improve the uptake of vaccines using an experimental design, focusing on the Human Papillomavirus (HPV) vaccine, which is highly effective in preventing HPV-related cancers. However, low HPV vaccination rates among adults remain a significant public health challenge. Although randomized controlled trials (RCTs) have demonstrated that interventions can increase vaccine uptake in children, few RCTs have been conducted among adults.
To address this gap, a multidisciplinary investigative team with expertise in communication, medicine, nursing, and behavior-change intervention research will conduct a survey experiment and a cluster randomized controlled trial. First, a national sample of adults ages 18 to 45 who have not received the HPV vaccine or are unsure of their vaccination status will participate in a survey experiment to identify the most promising theory-based messages to strengthen HPV vaccine intentions. The two messages associated with the largest increases in vaccination intentions will then be selected for further testing.
Next, 16 Penn Medicine primary care clinics will participate in a factorial cluster randomized controlled trial to test patient-level and clinic-level interventions designed to increase HPV vaccine uptake. Patient-level interventions will include theory-based text messages and a reminder-only message condition. The clinic-level intervention will provide healthcare providers with feedback on missed opportunities for HPV vaccination and a toolkit to support strong HPV vaccine recommendations.
The study will evaluate whether these interventions increase receipt of the first HPV vaccine among eligible adult patients and whether combining patient-directed messages with the clinic-level intervention further increases HPV vaccination. HPV vaccination will be assessed using Penn Medicine electronic health records and, when needed, patient self-report.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- University of Pennsylvania
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 18-45 years old
Exclusion Criteria:
- Under 18 and over 45 years old
- Received HPV vaccine or unsure about receipt
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: HPV Message 1 + Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. |
|
Experimentell: HPV Message 1 + No Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Experimentell: HPV Message 2 + Clinic Intervention
|
A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Experimentell: HPV Message 2 + No Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Experimentell: HPV Message 3 + Clinic Intervention
|
A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Experimentell: HPV Message 3 + No Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Aktiv komparator: Control Message + Clinic Intervention
|
A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. An attention-matched control text-message condition that does not contain the theory-based HPV vaccination messages being evaluated. |
|
Aktiv komparator: Control Message + No Clinic Intervention
|
An attention-matched control text-message condition that does not contain the theory-based HPV vaccination messages being evaluated. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Aim 1 - Intention to Vaccinate
Tidsram: Immediately after exposure to the assigned message
|
Assessed using a three-item validated HPV Vaccination Intention Scale. The three items evaluate the participant's intent, plan, and likelihood to receive the HPV vaccine within the next 6 months. Responses for each item were recorded on a 5-point Likert scale. A composite intention score was calculated as the mean of the three items, with total scores ranging from 1 to 5. Higher scores indicate a better outcome (a greater intention to receive the HPV vaccine). |
Immediately after exposure to the assigned message
|
|
Aim 2 - Receipt of HPV Vaccine
Tidsram: From intervention initiation through 9 months of follow-up
|
Receipt of HPV vaccine during the follow-up period, determined from HPV vaccination documentation in the electronic health record or patient self-report. |
From intervention initiation through 9 months of follow-up
|
Samarbetspartners och utredare
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Patologiska processer
- Sjukdomsegenskaper
- Infektioner
- Virussjukdomar
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- DNA-virusinfektioner
- Tumörvirusinfektioner
- Patologiska tillstånd, tecken och symtom
- Beteende
- Behandlingsefterlevnad och efterlevnad
- Hälsobeteende
- Avslag på behandling
- Vaccinationsvägran
- Papillomavirusinfektioner
- Kommunikation
- Vaccinationstveksamhet
Andra studie-ID-nummer
- UPCC 02026
- 856892 (Annan identifierare: University of Pennsylvania IRB)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .